SCHEMBL9890750

SCHEMBL9890750

CNC(=O)Cc1ccccc1-c1cccc(OC)c1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MTNR1A P48039 2/20 0.54
MTNR1B P49286 1/20 0.54
DGAT2 Q96PD7 7/20 0.49
PTGDR2 Q9Y5Y4 1/20 0.48
ALDH1A1 P00352 3/20 0.48
KDM4E B2RXH2 3/20 0.48
KMT2A Q03164 2/20 0.48
NPSR1 Q6W5P4 1/20 0.48
L3MBTL1 Q9Y468 1/20 0.48
HTR7 P34969 1/20 0.48
MAPT P10636 3/20 0.47
HSD17B10 Q99714 2/20 0.47
MEN1 O00255 1/20 0.47
USP2 O75604 1/20 0.47
NPY2R P49146 1/20 0.47
LMNA P02545 1/20 0.47
CYP1A2 P05177 1/20 0.46
POLB P06746 1/20 0.46
CYP3A4 P08684 1/20 0.46
CYP2C19 P33261 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2391528 0.85 PTGDR2 (0.51) DGAT2PTGDR2
SCHEMBL9890742 0.83 MTNR1A (0.50) MTNR1AMTNR1BPTGDR2ALDH1A1KDM4E
SCHEMBL2394292 0.82 FFAR1 (0.47) ALDH1A1KMT2AL3MBTL1HTR7MAPT
SCHEMBL8281062 0.81 HTR7 (0.52) MTNR1AMTNR1BALDH1A1KMT2AHTR7
SCHEMBL2397419 0.81 KMT2A (0.51) ALDH1A1KDM4EKMT2AL3MBTL1LMNA
SCHEMBL2393439 0.81 SMN1; SMN2 (0.46) KMT2AHTR7MAPTMEN1LMNA
SCHEMBL9890716 0.81 CHRM1 (0.62) L3MBTL1HTR7HSP90AA1HSP90AB1
SCHEMBL9890735 0.81 CHRM1 (0.44) ALDH1A1KMT2AL3MBTL1MAPTMEN1
SCHEMBL8643629 0.80 HTR7 (0.52) MTNR1AMTNR1BDGAT2ALDH1A1HTR7
SCHEMBL9890751 0.78 PTGER1 (0.52) ALDH1A1KMT2AMAPTHSD17B10MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120142771-A1 BIPHENYLACETAMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2012-06-07 US disclosed
US-20110224304-A1 BIPHENYLACETAMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2011-09-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120142771-A1 BIPHENYLACETAMIDE DERIVATIVE HRH3, KCNH3, BRPF3 MTNR1A 376/4885MTNR1B 309/4885DGAT2 2271/4885
US-20110224304-A1 BIPHENYLACETAMIDE DERIVATIVE HRH3, KCNH3, BRPF3 MTNR1A 376/4885MTNR1B 309/4885DGAT2 2271/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.